Navigation Links
MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers
Date:12/2/2010

, which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development of BMN 673, including the timing of the clinical trials of the candidate, and the possible efficacy of such candidate. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned clinical and preclinical studies related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trad
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arbor Pharmaceuticals Completes $34.8 Million Financing
2. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. Apollo Endosurgery Completes First-in-Human Cases With New OverStitch™ Endoscopic Suturing System
5. Boston Scientific Completes Acquisition of Asthmatx
6. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
8. Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
9. InfraReDx Completes $21 Million Equity Financing
10. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
11. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... , July 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ... conference call and webcast at 5:00 p.m. Eastern Time ... to discuss second quarter 2015 financial results and provide ... after the NASDAQ Global Select Market closes that day. ... dialing 877.643.7155 for domestic callers and 914.495.8552 for international ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 6, 2015, at ... the second quarter ended June 30, 2015, and to ... vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... July 28 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... quarter and fiscal year 2010, ended June 30, 2010 on Tuesday, ... , , ... / 5:00 p.m. ET and will be hosted by Euan S. Thomson ...
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 2Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 3Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 4HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/30/2015)... ... , ... When responsible for the care of an aging loved one, summer ... mind: What happens if mom falls? Who will remind Dad to take his medications? ... But not taking time away from caregiving responsibilities can lead to bigger problems – ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... On July ... meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately ... event of an overdose is largely perpetuating the heroin crisis in North Florida. The ...
(Date:7/30/2015)... Austin, Texas (PRWEB) , ... July 30, 2015 ... ... Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that ... Dyslipidemia have been published for use on the CDISC website . These ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... pigs has been identified by scientists in South Korea – ... //microbiology, following the findings of J.J. Shin and colleagues at ... pathogen, the H3N1 influenza A virus that can be found ... reassortment of influenza viruses. The virus, which was first identified ...
... a new treatment “target” to help millions of asthma ... research on certain white cells in the body that ... experienced by asthma patients. ,The scientists, at ... Cincinnati Children’s Hospital Medical Center, report their results in ...
... alert the antennae of call centre employees, and cause them ... call // centers in UK, who are now in a ... damage in their employees. This revelation is indeed a wake ... are undoubtedly risking an important faculty of theirs, gravely. , ...
... increase the chances of heart attack, but cocaine lifts the ... study reported that ‘while sex causes very little increased risk ... 20-folds’. ,The review by University of Sydney and ... attacks, including sexual activity, cocaine use, pollution, heavy meals, and ...
... has reached 80 with the recent death //of a 5-year ... non-governmental groups. It is believed that the five-year-old boy had ... ,Chief physician of the regional HIV/ AIDS prevention and ... that a child infected with HIV was registered in Turkestan, ...
... boards (DHBs) who ten days ago walked off their jobs, ... unresolved. // ,Anne Aitcheson, national co-ordinator of contingency planning ... back to normal at affected hospitals. ,She said, ... are booked and we will be back to normal." ...
Cached Medicine News:Health News:Scientists Pursue New Treatment For Asthma Sufferers 2Health News:Scientists Pursue New Treatment For Asthma Sufferers 3Health News:Radiographers Pay Parity Disputes Still Unresolved 2
Includes one aluminum pediatric eye shield and one eye garter shield cover. Packaged 50 per box. White only....
Non-linting, quick absorption and rounded corners. Tapered malleable handle. Dispenser carton contains 25 envelopes, each envelope contains 10 sponges packaged sterile in Tyvek peel-back pouch....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Medicine Products: